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Abstract
Background: In many low- and middle-income countries, where tobacco use is common, tuberculosis is also a
major problem. Tobacco use increases the risk of developing tuberculosis, secondary mortality, poor treatment
compliance and relapses. In countries with TB epidemic, even a modest relative risk leads to a significant
attributable risk. Treating tobacco dependence, therefore, is likely to have benefits for controlling tuberculosis in
addition to reducing the non-communicable disease burden associated with smoking. In poorly resourced health
systems which face a dual burden of disease secondary to tuberculosis and tobacco, an integrated approach to
tackle tobacco dependence in TB control could be economically desirable. During TB screening, health
professionals come across large numbers of patients with respiratory symptoms, a significant proportion of which
are likely to be tobacco users. These clinical encounters, considered to be “teachable moments”, provide a window
of opportunity to offer treatment for tobacco dependence.
Methods/Design: We aim to develop and trial a complex intervention to reduce tobacco dependence among TB
suspects based on the WHO ‘five steps to quit’ model. This model relies on assessing personal motivation to quit
tobacco use and uses it as the basis for assessing suitability for the different therapeutic options for tobacco
dependence.
We will use the Medical Research Council framework approach for evaluating complex interventions to: (a) design
an evidence-based treatment package (likely to consist of training materials for health professionals and education
tools for patients); (b) pilot the package to determine the delivery modalities in TB programme (c) assess the incre-
mental cost-effectiveness of the package compared to usual care using a cluster RCT design; (d) to determine bar-
riers and drivers to the provision of treatment of tobacco dependence within TB programmes; and (e) support
long term implementation. The main outcomes to assess the effectiveness would be point abstinence at 4 weeks
and continuous abstinence up to 6 months.
Discussion: This work will be carried out in Pakistan and is expected to have relevance for other low and middle
income countries with high tobacco use and TB incidence. This will enhance our knowledge of the cost-
effectiveness of treating tobacco dependence in patients suspected of TB.
Trial Registration: Trial Registration Number: ISRCTN08829879
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Tobacco epidemic
Eight out of every ten smokers live in low- and middle-
income countries[1]. In several of these countries,
tobacco use is on the increase. Consequently, 70% of the
projected mortality secondary to tobacco use is likely to
be borne by low- and middle-income countries[1]. In
addition, people die at an earlier age in such countries,
causing the loss of 20-25 years of productive life[2].
Cost of cigarettes is relatively high in low- and middle-
income countries compared to food and other essential
commodities, resulting sometimes in their substitution.
Therefore, tobacco use puts enormous burdens on
countries’ already ailing economies and contributes to
existing impoverishment. The WHO Framework Con-
vention on Tobacco Control (FCTC)[3] uses interna-
tional law as a lever to establish policies to reduce both
supply and demand for tobacco[4]. The key recommen-
dations include offering help to people who want to quit
tobacco use[5].
Treating tobacco dependence
It has been suggested that at least 180 million deaths
related to tobacco can be avoided by reducing current
tobacco consumption by 50%. Surveys suggest that three
out of four smokers wish to quit and one-third attempt
to quit every year[6]. However, only 1-3% are successful
if attempting on their own[7]. There is overwhelming
evidence for the effectiveness and cost-effectiveness of a
number of psychological and pharmacological treat-
ments for tobacco dependence[8,9]. The evidence sug-
gests that both behavioural and pharmacological
therapies have the potential to double the quit rates
among smokers and are highly cost-effective[10]. In low
and middle-income countries, spontaneous quit rates
are lower suggesting an even greater need for support-
ing people who wish to quit, and an opportunity to have
a higher health benefit.
One of the several challenges in treating tobacco
addiction in low- and middle-income countries is the
lack of resources and governmental funding for the
implementation of effective interventions. Many coun-
tries facing a tobacco epidemic are also confronting
other challenges related to communicable diseases and
nutrition-related disorders. Therefore, it may not be
possible for countries with limited resources to shift
priorities. However, existing programmes (such as TB
control) can be utilised to extend their role to tobacco
control with minimum investment. The WHO recom-
mends integration of such tobacco cessation interven-
tions into an overall policy on tobacco control and
incorporation of these programmes into general health
care[8].
Tobacco dependence and tuberculosis
Smoking is closely related to tuberculosis (TB), another
big killer. TB is a major public health issue in several
countries where nicotine use has reached epidemic pro-
portions. For example, 15% of all new TB cases in the
world occur in China where nearly two thirds of men
use nicotine[11]. Smoking prevalence is generally high
among TB patients. In India, TB patients are three
times as likely to be smokers than rest of the population
[12].
A number of recent reviews have suggested that
smoking is strongly associated with increased rates of
both TB infection and TB disease [13-18]. Passive smok-
ing is a particular risk factor especially in children. One
study highlighted the high risk of acquiring TB infection
among children who live with other adults who have
had TB and were also exposed to second hand cigarette
smoke[19]. Smoking leads to faster progression and
poorer prognosis of tuberculosis[20]. In relation to TB
outcomes, smokers are also less likely to adhere to TB
treatment and more likely to relapse after successfully
completing treatment according to some studies[14].
Smokers have also been shown to have a high risk of
dying secondary to tobacco use[13,16]. Since the pro-
portion of people using nicotine is very high in coun-
tries where TB is a major problem, even a modest
relative risk amounts to considerable attributable risk of
infection to the population[18]. In countries where TB
is endemic and the vast majority of the population has
been exposed to TB at some point in their life, tobacco
use is likely to lead to progression or reactivation of TB
infection. Patients, especially males, who are diagnosed
with latent TB infection are less likely to adhere to their
treatment and more likely to progress to full blown
tuberculosis[21].
Treating tobacco dependence among TB patients and TB
suspects
The association between TB and tobacco epidemic
implies that addressing nicotine use in global TB control
is likely to be beneficial for controlling TB as well as
chronic diseases. It therefore makes sense that brief
advice or any other available treatment for smoking ces-
sation should be included in the management plan of
TB patients. There are unmet opportunities for preven-
tion and control of tobacco use among TB patients.
During a typical course of treatment for TB, patients are
in regular contact with health professionals for at least
six months. Patients are considered to be more receptive
to health education messages and willing to modify their
health behaviour when they are ill[22]. Patients’ contact
with a health professional whilst they are being investi-
gated for TB is considered as one of the “teachable
moments” which is highly likely to trigger behaviour
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and treatment on smoking cessation for all patients
coming in contact with TB services and not just TB
patients.
Research problem and justification
Before recommending TB programmes to incorporate
identification and treatment of tobacco use, it is highly
desirable and ethical to assess the feasibility of such an
intervention. We found one such study conducted in
Sudan that examined the feasibility of adding a simple
cessation intervention to the general health care provi-
sion for TB patients in a poorly resourced health sys-
tem[24]. The study found that the health professionals
were willing and able to support a high proportion of
TB patients (44%) in smoking cessation. There is no
published research to our knowledge that has evalu-
ated the cost-effectiveness of identifying and treating
tobacco addiction among TB patients or TB suspects
using a randomised controlled trial. Such research is
highly desirable. It will assist programme managers
and policy makers to see how such an integrated
approach between the two programmes can be effec-
tively and efficiently incorporated. We plan to conduct
this study in Pakistan, a low income country with a
high incidence of TB and a high prevalence of tobacco
use[25]. Recent emphasis on both Tobacco and TB
control provides a window of opportunity to evaluate
innovative solutions for both public health problems
and make these accessible to the population in
Pakistan.
Research questions
1. What is the effect of a tobacco cessation interven-
tion, based on WHO’s ‘five steps to quit’ model, on
patients’ point and continuous abstinence from
tobacco use? [Effect evaluation]
2. To what extent do the health professionals com-
municate risks of tobacco use and benefits of its ces-
sation to their patients? What are their experiences
a n do p i n i o n sa b o u tt h i ss t r a t e g y ?[ P r o c e s s
evaluation]
3. How do patients experience the intervention for
tobacco addiction? [Ethical evaluation]
4. What is the incremental cost-effectiveness ratio of
the intervention for tobacco addiction compared to
usual care? [Economic evaluation]
General Objectives
We aim to develop and trial a complex intervention to
reduce tobacco dependence among TB suspects based
on the WHO ‘five steps to quit’ model. Although this
work will be carried out in Pakistan, we expect our find-
ings will have relevance to tobacco control in other low
and middle income countries.
Specific Objectives
We will follow the Medical Research Council framework
(see explanation in Methods section) for designing and
evaluating complex interventions. Our specific objectives
are:
1. To use qualitative methods to inform the develop-
ment of an intervention based on WHO’s ‘five steps
to quit’ model (Phase I).
2. To develop and pilot this intervention which is
likely to consist of: (a) an illustrative desk-guide (on
patient assessment, education and treatment of
tobacco dependence) and a training manual on this
desk-guide for training of health professionals; and
(b) leaflets for patients and others in the house con-
taining information on the harmful effects of
tobacco and advice on stopping its use, implying
both cessation and prevention of tobacco use (Phase
II).
3. To evaluate the incremental cost-effectiveness
ratio of this intervention compared to usual care by
estimating the proportion of people successfully
quitting tobacco use (Phase III).
4. To determine barriers and drivers to the provision
of treatment of tobacco dependence within TB pro-
grammes (qualitative component of Phase III).
5. To promote and support long term implementa-
tion of this intervention (Phase IV).
Methods/Design
Conceptual and theoretical framework
We propose to evaluate the cost-effectiveness of a
multi-faceted intervention to control tobacco depen-
dence, which by definition is a ‘complex’ intervention.
Such interventions in general consist of several inter-
connected elements which are all important for their
functioning[26]. Therefore, it is difficult to specify an
active ingredient in a complex intervention. Evaluation
is generally difficult as complex interventions are not
easy to define, develop, document, standardise and
reproduce[27]. MRC has produced a framework which
divides such evaluation into different phases that can be
sequential or iterative. Each phase answers a specific
question that leads to the next phase of the evaluation.
The objectives in our study align with different phases
of this framework as follows:
1. Phase I will help us in identifying the likely beha-
viour change-elements in relation to tobacco use for
the intervention especially the training package for
professionals (desk-guide and training manual), and
the information leaflet for patients.
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intervention to allow us to refine and standardise it,
test its feasibility in a resource-limited situation and
test the feasibility of various (research and routine)
data collection tools.
3. Phase III will consist of a cluster randomised trial
to assess the effectiveness of the intervention, a cost-
ing study to assess its cost-effectiveness, and a sub-
sequent qualitative study to identify barriers and
facilitators in delivering the intervention.
4. Phase IV will identify key activities required to
scale up the intervention.
Objective 1
To use qualitative methods to inform the development
of an intervention based on WHO’s five steps to quit
model (Phase I)
Key activities
From a health systems point of view, we would be
interested in understanding the local health care con-
text for delivering the intervention. This would involve
issues like current working environment, staffing, and
workload issues. We will also explore the possibilities
of funding NRT and bupropion, their registration and
addition to the essential drug list. We will do this
through conducting a workshop with the Tobacco
Control Programme and other stakeholders at the
start.
We will use qualitative approaches to understand: (a)
the extent to which health professionals particularly
doctors currently convey risks of tobacco use and bene-
fits of its cessation to their patients; (b) how they per-
ceive their own role, knowledge, skills and confidence in
conveying these messages; (c) how their own behaviour
towards tobacco use is going to affect their attitude
towards patients using tobacco and the advice they
might offer; (d) which professional group would be most
appropriate to provide the different elements of the
package e.g. initial advice, motivation assessment, coun-
selling, follow-up; and (e) what would be most useful
form and content of training package and tools to sup-
port them in this process. Among patients, especially
presenting to primary care with respiratory complaints,
we are interested in understanding: (a) to what extent
they currently understand the risk of tobacco use and
benefits of its cessation; (b) in what form and detail they
would like to receive such information from health pro-
fessionals; (c) what kind of visual images will be evoca-
tive but also culturally appropriate if used in education
materials; (d) what are their common misconceptions
about tobacco use; and (e) what is their attitude towards
smoking cessation aids including willingness to pay for
NRT (f) do women and men respond differently to
advice by physicians versus others, and by advisors
based on gender
We will use focus groups to identify common themes
as these allow participants to interact with each other
and stimulate and generate themes which are sometimes
not possible with interviews[28]. We are not only inter-
ested in “what they say they do” (their belief system) but
also in “what they really do” (their behaviour). FGDs are
particularly useful in this context as participants often
challenge each other and therefore provide more in-
depth understanding of inconsistencies between
reported and actual behaviour. We are also interested in
the social and cultural constraints that modify behaviour
and are generally brought up in FGDs.
Settings
Focus groups will be conducted in health centres which
will be participating in the subsequent phases of the
study.
Participants
We will conduct two focus groups each from the follow-
ing three categories of informants i.e. six focus groups in
total. We will invite 6-8 participants for each focus
group from the following:
1. Doctors
2. Nurses and health technicians (paramedical staff)
3. Patients (tobacco users) with respiratory symp-
toms (one with males and other with females)
Sampling
Purposive sampling will be used to understand the
breadth of variation as well as the typical attitudes and
behaviours among professionals and patients. We will
try to have participants from similar social class and
backgrounds to allow enrichment of the data with mini-
mum censorship.
Data collection
FGD will be facilitated by the research officer who will
use a FGD topic guide which will be piloted with a
group of health professionals and patients in another
health centre. FGD will be tape-recorded.
Data analysis
We will use a sequential focus groups and analysis pro-
cess so that the later focus groups can be informed by
and test themes emerging from the earlier focus group
discussions. We will conduct an inductive analysis by
indexing through generating codes and identifying
themes from the narrative text. Analysis will be con-
ducted in the original language to identify and link
themes. All narratives will be analysed separately first,
followed by comparing and linking themes generated
during the analysis across narratives.
Outputs
1. A training package and tools (both format and
content) which are context specific and are likely to
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skills, motivation and confidence to convey the risks
of tobacco use and the benefits of cessation to
patients.
2. Culturally appropriate messages and the form in
which they are communicated to patients that is
likely to challenge their misconceptions, answer
common queries, provide the right depth of knowl-
edge, their attitude towards smoking cessation aids
including willingness to pay for them and motivation
for them to modify their tobacco-related behaviour.
3. An understanding of health system constraints
and drivers in delivering the intervention including
possibilities of paying for NRT and bupropion
Objective 2
To develop and pilot this intervention which is likely to
consist of: (a) an illustrative desk-guide (on patient
assessment, education and treatment of tobacco depen-
dence) and a training manual on this desk-guide for
training of health professionals; and (b) leaflets for
patients and others in the house containing information
on the harmful effects of tobacco and advice on stop-
ping its use, implying both cessation and prevention of
tobacco use (Phase II).
Key activities
These can be divided into development and pilot.
In the development Two different processes will be
used to develop products for health professionals (train-
ing module & desk-guide) and patients (illustrative edu-
cation tool & leaflet) respectively. We will convene a
“local working group” of national (Pakistani) experts in
tobacco control, primary care, health systems and dis-
trict health services management, the district TB pro-
gramme coordinator and primary care physicians and
paramedics. This group will use the nominal group
technique (a face-to-face group process technique for
gaining consensus)[29] to agree the form and contents
of the training module and desk-guide. We will use a
decision framework based on the usefulness and applic-
ability of the interventions. We will commission a local
professional media company to develop illustrative edu-
cation tools and leaflet. We will make sure that the edu-
cation tools are prepared to be appropriate for both
urban and rural population acknowledging different pat-
terns of tobacco use and literacy. If necessary, we will
produce separate versions of such tools. The product
specifications will be based on the outcomes of the
focus groups. The final product will be reviewed and
approved by the local working group.
With permission, we will also make use of any existing
materials developed by other international agencies,
research groups or countries (such as the UK) which
can be adapted to the context defined in the previous
phase. Once we have developed draft materials, we will
get external review from other national and interna-
tional experts in the field.
In the pilot The intervention will be delivered in six
health centres (three urban, three rural). A decision to
include these centres in the main trial will be taken at
the end of the pilot depending upon required alterations
in the intervention. In these centres we will introduce
new tobacco use registers/questionnaires including
queries such as: (a) current tobacco use (yes or no); (b)
amount of tobacco use; (c) whether the patient is will-
ing to try to stop tobacco use (yes or no); and (d)
whether the patient has been registered to receive “five
steps to quit” intervention[30]. We will develop and use
separate data collection tools for people registered to
receive the intervention. This will include a patient card
filled in for every tobacco user who is willing to try to
quit and a register of all such patients[30]. This will
help us in assessing the feasibility of all these modifica-
tions and additions. 25 consecutive attendees who con-
sent to participate and meet the inclusion criteria will
be recruited in each centre (n = 100) and offered the
intervention. Training evaluation of health professionals,
in-depth interviews with patients and health profes-
sionals, and observations of the health professionals
delivering intervention, will be carried out to identify:
(a) any structural or processes barriers to the imple-
mentation; (b) modifications required in the data collec-
tion tools and systems; and (c) any modifications
required in the training package based on participant
observation and training event evaluation; (d) any
changes in the assigned roles of health professionals
within the package; and (e) any modifications required
in desk-guide, patient education tool and leaflets based
on observation of care delivery and discussion with care
providers.
We will also estimate the validity of the subjective
assessment of abstinence by using a cotinine test (or CO
test) on all participants at follow up during this pilot.
Depending upon the validity, we will decide to either
use cotinine test (or CO test) in the actual trial or just
the subjective assessment as a proxy.
Ultimately, based on the results of this pilot, we will
develop a final version of the various components of the
intervention. We will also modify the process for deli-
vering the intervention if necessary.
Outputs
1. A refined training module and an illustrative desk-
guide on patient assessment, education and treat-
ment of tobacco dependence for health professionals’
use.
2. An illustrative education tool for patients
3. Leaflets for patients and others in the house con-
taining information on the harmful effects of
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been piloted
4. Additional leaflet for the patient’sf a m i l yt h a tw i l l
include an explanation of the impact of second hand
smoke on the patient and others
5. A revised and refined process for delivering the
intervention in the study sites
6. Appropriate and revised data collection tools and
systems.
The Intervention and its key components
FIVE STEPS TO QUIT - The Intervention Model: This
is based on the evidence-based recommendations for
treatment of tobacco addiction published by WHO in
2001[8]. The same approach is being advocated by
IUATLD, National US guidelines and NICE in the UK
[23,31]. This model relies on assessing personal motiva-
tion to quit tobacco use and uses it as the basis for
assessing suitability for the different therapeutic options
for tobacco dependence. Thus, the approach maximizes
the efficient use of nicotine replacement therapy (NRT)
and bupropion.
Key Components: We would like to develop compo-
nents of the “Five Steps to Quit” intervention model on
the basis of the following principles:
● Based on best available evidence and following an
approach recommended by international agencies such
as WHO and IUATLD[23].
● Can be delivered in primary care setting by non-spe-
cialist health care staff (doctors or other non-medical
personnel) integrated in their routine healthcare
provision.
The intervention model consists of five key steps
1. Asking about the status of nicotine use;
2. Advising about the benefits of stopping nicotine
use;
3. Assessing the motivation to stop its use;
4. Assisting in stop attempts through various thera-
peutic options; and
5. Arranging follow-up
Examples of the specific components for each step of
the intervention are given in Appendix 1; this is a gen-
eral guide only and modifications will be made during
the development of the intervention.
Objective 3
To evaluate the incremental cost-effectiveness ratio of
these interventions compared to usual care by estimat-
ing the proportion of people successfully quitting
tobacco use (Phase III).
Hypothesis
For this part of the project, we hypothesize that the ‘five
steps to quit’ intervention (with or without offering the
therapeutic option) will be more effective and cost-effec-
tive in getting people who are suspected of tuberculosis
to quit nicotine use and remain quitters at both 4 weeks
and six months after the treatment compared to usual
care and information leaflet.
Settings
The study will be conducted in health centres in the
public sector which are designated TB diagnostic centres
(as per WHO’s definition) in rural and urban settings in
two districts in Punjab, Pakistan. This has been the set-
ting of a number of research activities carried out by the
investigating team over the last 12 years mainly in
tuberculosis. Diagnostic centres, in a typical district in
Punjab, are generally:
● Rural health centres - rural settings
● Tehsil headquarter hospitals - urban settings
Centres are typically staffed by one to three doctors,
nursing staff, laboratory technician, pharmacist and
community health workers. They are also equipped with
a basic microbiology laboratory capable of examining
sputum for AFB. The outpatient departments are open
to the population of the catchment area including refer-
rals from Basic Health Units (a single doctor manned
primary care health centre). Patients with suspected
tuberculosis once seen are screened with two/three spu-
tum examinations. If diagnosed with TB, they are regis-
tered and commenced on anti-tuberculosis therapy.
Study Design
To deliver ‘five steps to quit’ intervention (with or with-
out offering the therapeutic option), individual patients
cannot be randomised to the intervention and control
arms within health centres due to the possibility of con-
tamination. The most suitable design to assess its effec-
tiveness is a cluster randomised controlled trial (RCT).
The overall design is summarised in the trial flow chart
in Figure 1. We propose to have three arms in the trial:
(a) control arm - usual care and an information leaflet;
(b) intervention arm 1 - ‘five steps to quit’ that includes
offering therapeutic option; and (c) intervention arm 2 -
‘five steps to quit’ that excludes therapeutic option). We
propose to select a total of 33 diagnostic centres (11 at
each control and the two intervention arms) and to
recruit 50 patients with suspected tuberculosis (see the
section on sample size below).
Participants and Sampling
The sampling frame will consist of all TB diagnostic
health centres that are approached for this study and
their doctors and other paramedical staff have expressed
willingness to participate. Access to these diagnostic
centres will be facilitated by one of the investigating
partner organisations, ASD, which has been given the
responsibility of implementing the DOTS strategy in 18
districts in Punjab. Health centres in the sampling frame
will be stratified according to rural (RHC) and urban
Siddiqi et al. BMC Public Health 2010, 10:160
http://www.biomedcentral.com/1471-2458/10/160
Page 6 of 13location (THQ). 11 health centres will be randomly allo-
cated to each of the two intervention arm and the con-
trol arms, using computer generated random number
lists by an independent scientist.
In each health centre, we will approach adult patients
(≥18 years), who cough for 3 or more weeks and are
therefore suspected and screened for pulmonary tuber-
culosis. We would aim to recruit at least 50 patients
from each centre over a period of three to six months.
Patients will be provided with both verbal and written
information about the study and only those who consent
will be recruited in the study.
Patients whose condition requires hospital admission
or other urgent medical attention will be excluded.
Patients will be approached and recruited each day.
Delivery of the intervention
We propose to use a systematic, standardised approach
to deliver ‘five steps to quit’ to make it effective and
equitable[30]. It is envisaged that the intervention will
be primary delivered by the TB DOTS facilitator based
in the diagnostic centre with the help and under the
supervision of the primary care doctor (Table 1). He
will assess patients’ eligibility for the study and send
them to the TB DOTS facilitator for further assessment.
Figure 1 Trial flow chart.
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written information about the study and invited to parti-
cipate. Patients who agree to take part will be taken
through different components of the ‘five steps to quit’
programme in two appointments. Patients in interven-
tion arm 1 will also be offered therapeutic option
(Bupropion) and such patients will be referred to the
primary care doctor for assessing suitability and pre-
scribing Bupropion.
The TB DOTS facilitators and primary care doctors
will be given a training course (using training manual)
on the “five steps to quit” p r o g r a m m eo nt h eu s eo f
desk-guide and focusing on[30]:
● The scientific basis of the intervention
● Techniques to enquire about the status of tobacco
use
● Providing brief advice on the benefits of stopping its
use through visual images
● Approaches to assess nicotine dependence and moti-
vation to quit
● Using this motivation to propose various treatment
options explaining their pros and cons
● Training in the use of available pharmacotherapies
and other cognitive-behavioural strategies
● The procedure for follow-up and other technical and
organisational aspects.
● Familiarity with the recording and reporting system
such as revised records and new tools
Training of TB DOTS facilitators will also focus on
the brief counselling techniques based on cognitive-
behavioural model[32]. A simple desk-guide will be pro-
vided with simple algorithms and instructions for health
professionals to follow “five steps to quit” programme.
This will also include glossy images to support patients
in understanding the benefits of stopping smoking. The
TB DOTS facilitator, for all eligible patients, will be
responsible for:
● Assessment of the status of their tobacco use
through a checklist of questions
● Advising on benefits of quitting using visual and
written educational material
● Assessment of willingness for inclusion in the study
and motivation to quit using a simple scoring card
● Registration and recording of demographics and
contact details
● Structured counselling using a desk guide and
patient planner
● Giving a quit date after a week
On the subsequent visit in a week’s time, TB DOTS
facilitator will be responsible for
● assessing the status of their tobacco use
● Sharing their experience of attempting to quit, listen
to the difficulties they had and providing supportive
counselling to help cope with the difficulties
● Referring them to doctor if the intervention arm
includes therapeutic option
● Arranging follow up in a month’s time.
At follow ups at week 5 and 25, TB DOTS facilitators
will be responsible for
● Reassessing status of nicotine use and recording it in
the tobacco use questionnaire/register
● Reviewing treatment and other options
● Rearranging follow up as per desktop guide.
In the intervention arm 1, the primary care doctors, in
addition to supervising TB DOTS facilitators, will be
responsible for assessing and prescribing therapeutics
(Bupropion) to patients who wish to quit and are being
referred by the TB DOTS facilitators. All patients on
treatment will have an additional follow up visit at week
8. In intervention arm 2, doctors will be only responsi-
ble for supervising TB DOTS facilitators. They will be
provided with the appropriate training and relevant
materials.
Apart from the relevant training and materials, health
professionals will not be provided with any other incen-
tive, financial or otherwise. However, treatments packs
will be provided from the research budget. The research
officer will also organise regular supervisory visits to
Table 1 Follow up and contacts with health professionals
Trial arms First contact FU at week 1 FU at week 5 FU at week 8 FU at week
25
Intervention 1 (brief psychological intervention +
therapeutics)
Assess eligibility at the
laboratory
TB DOTS
facilitator
TB DOTS
facilitator
TB DOTS
facilitator
TB DOTS
facilitator
TB DOTS facilitator Doctor Doctor (if
necessary)
Doctor
Intervention 2 (brief psychological intervention
only)
Recruitment at the
laboratory
TB DOTS
facilitator
TB DOTS
facilitator
TB DOTS
facilitator
TB DOTS facilitator
Control (usual care + leaflet) Recruitment at the
laboratory
TB DOTS
facilitator
TB DOTS
facilitator
TB DOTS
facilitator
TB DOTS facilitator
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dures. Monthly cluster meetings of the health profes-
sionals involved will also be organised to discuss
progress and potential problems.
The Control Arm
Participants in the control arm will also be recruited
from those who are suspected of TB and screened using
sputum examinations. The changes in the relevant regis-
ters will be made to record the status of nicotine use
and health professionals will be given instructions on
recording it on-site. The TB DOTS facilitators in con-
trol diagnostic centres will be provided with patient edu-
cation leaflets to be given out to all patients recruited in
the study. Apart from recording their status of nicotine
use and arranging follow up at week 1 and 5, they will
be provided usual care. No other components of the
intervention will be delivered. We do not anticipate a
significant risk of contamination, i.e. patients moving
from one diagnostic centre to another, due to the geo-
graphical spread of facilities, and because no publicity
will be produced regarding the availability of the treat-
ment package in other facilities. In addition, we do not
anticipate a significant benefit (other than what has
been recorded previously in controls) in the control arm
given that asking about nicotine use and providing
information leaflets, are not, by themselves, sufficient to
lead to stopping nicotine use.
Outcomes
These are as follows[30]:
1. Point abstinence at 4 weeks: The proportion of
trial participants who have completely given up all
forms of nicotine use at four weeks after the com-
pletion of bupropion and/or brief psychological
intervention
2. Continuous abstinence up to 6 months: Propor-
tion of trial participants who remained abstinent
from 4 weeks onwards up to six months
3. We will also measure tobacco use e.g. number of
cigarettes smoked per day to estimate any reduction
in tobacco use secondary to the intervention
4. Secondary outcomes will include incidence of var-
ious adverse affects secondary to therapy
5. Economic outcomes will be assessed in terms of
healthcare cost to get one person to stop smoking at
four weeks. Healthcare cost will include the treat-
ment cost, the average duration of health profes-
sionals’ time spent with the patients during
assessment, advice and counselling.
6. Process outcomes will include: the proportion of
tobacco users who decide to quit and registered to
receive ‘five steps to quit’ intervention; and the pro-
portion of people registered who continue follow-up
for the full period planned
Data collection
Our pilot study will determine the feasibility of our pro-
posed tools to gather patient details and their status of
nicotine use at various appointments. The modified
tools will include:
1. ‘Five steps to quit” intervention cards and register
2. A separate tobacco use questionnaire/register to
record smoking status and motivation to quit
These approaches will allow us to record demographic
details including gender, socio-economic status, pre-
sence of other smokers in the house and workplace,
number of children at home, status of nicotine use,
motivation level, type of therapy offered, extent to
which therapy was used, adverse events and abstinence
at different end points. We would adapt some of the
tools already well described in the existing literature[30].
Patients who are subsequently diagnosed with TB will
be followed up regularly for their TB treatment and the
outcomes relevant to this study will be recorded during
those visits. Trial participants who are diagnosed as not
having TB and being given any of the three forms of
therapy will be asked to follow up at the intervals speci-
fied. Controls not diagnosed with TB and received only
usual care and a leaflet will be asked to return at 4
weeks to review their respiratory condition and to assess
their status of nicotine use. Attrition is a potential pro-
blem. After piloting in phase 2, patients’ mobile phone
numbers will also be recorded and those who are lost to
follow up will be contacted via their mobile phones to
assess their status of nicotine use. A high proportion of
Pakistanis possess mobile phones irrespective of socio-
economic status.
Similarly, at six months in both intervention and con-
trol arms, all patients who stopped tobacco use will be
contacted either via their mobile phones or landlines to
assess their smoking status. According to our estimate
this number will approximately be at least 264.
In order to estimate the average time spent by health
professionals in delivering ‘five steps to quit’ interven-
tion, our research officer will spent a day at each centre
to measure and record this time.
We will also record the gender and status of nicotine
use among all health professionals giving advice and
include a column in the above patient record tools to
record which health professional delivered which ele-
ment of the package.
Data analysis
Our research officer will collate data from all health
c e n t r e so nam o n t h l yb a s i sa n df e e dt h e mi n t oad a t a -
base created via SPSS kept on a mobile computer.
There will be an assessment of smoking status by inter-
vention category, analysed on an intention to treat basis.
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intervention and control arms at 4 weeks after the com-
pletion of the treatment and in controls 4 weeks after
they were given the leaflets. Further analyses will include
the comparison of continuous abstinence at six months
between the two arms. We will also estimate reduction
in tobacco use in both trial arms and compare to detect
any difference. Missing data on the outcomes will not
be inputted. Secondary analyses will investigate the use
of, and adherence with, the various forms of therapy.
Further sub-analyses will be carried out to detect differ-
ences in outcomes according to a number of variables
such as gender of the participants and providers, smok-
ing status of the provider, socio-economic status, exis-
tence of other smokers in the house or workplace and
presence of children at home. We are mindful that sam-
ple size estimation was not based on these sub-analyses
and therefore we may not be able to detect small differ-
ences in the outcomes according to these variables.
Sample size
We have estimated a sample size of 33 clusters (diag-
nostic centres) 11 in each arm of the trial. Each cluster
size will be 40. The actual number of patients recruited
in each cluster will be 50 patients with suspected tuber-
culosis each [assuming 80% will complete the trial up to
the review at 6 months as per study in Sudan[24]] to
give 80% power to detect a difference in quit rates of
20% in the intervention arm compared with 10% in the
control arm. The value of a is set at 0.05. The assump-
tions underlying this estimation are:
Quit rates We base our cessation rates on the cumula-
tive estimates in the recent systematic reviews con-
ducted by Cochrane Tobacco Addiction Group
[33-36]. According to these reviews, brief advice by
physicians, nicotine replacement therapy (NRT), and
use of bupropion can improve 6 month smoking quit
rates to 74%, 77% and 94% respectively. All three
approaches are part of our “5-steps to quit” interven-
tion and it is reasonable to expect an effect size of at
least 94% in our study. We would recruit our patients
from a group who are suspected of tuberculosis with
respiratory symptoms. It is likely that the quit rates
m a ye v e nb eh i g h e rt h a nt h ea b o v ei nb o t ht r e a t m e n t
arms. The trial of treating tobacco addiction in TB
patients in Sudan showed a sustained abstinence of
66% in the intervention group[24]. We also expect
some loss of effectiveness due to the fact that this is
not an efficacy trial and treatment will be provided
integrated within an existing programme. However, we
assume that this loss in effectiveness with the interven-
tion strategy applied to routine practice will be off-set
by higher quit rates in patients with respiratory symp-
toms suspected of tuberculosis. For the purpose of this
study, we assume that the quit rates at 6 months
would be at least 20% in the intervention group versus
10% in the control group.
Number of individuals per facility On average 50 new
TB patients are diagnosed every year in each diagnostic
centre. The number of patients suspected of tuberculosis
is generally ten times the number of patients diagnosed.
Therefore, recruiting 50 patients from each centre is
unlikely to pose any problems. In the study carried out
in Sudan, researchers were able to recruit and enrol 44%
of all TB patients[24]. We expect that on average one
patient will be recruited each day. Recruitment will take
place on five days of the week. After accounting for
holidays and unanticipated recruitment difficulties, we
expect to be able to recruit 50 participants with sus-
pected TB from each facility within a period of three
months.
Attrition Rates The sample size calculation incorpo-
rates an attrition rate of 20%. This is based on the
observations made in the trial of tobacco control in TB
patients in Sudan where less than 20% patients defaulted
over a period of six months. An intention to treat analy-
sis will account for any non-differential loss to follow
up. As part of DOTS, patients with diagnosed TB are
g e n e r a l l yf o l l o w e du pf o rap e r i o do fs i xm o n t h s .H o w -
ever, follow up of non-TB patients will be arranged as
part of the trial.
Intra-cluster variation The intraclass cluster coefficient
(ICC) of the outcomes is an important factor in estima-
t i o no ft h es a m p l es i z ef o rac l u s t e rR C T .I ti sg e n e r a l l y
estimated from the previous studies of smoking preva-
lence and its outcomes in similar settings. However, we
found very few studies reporting ICC in similar settings.
We use an ICC of 0.036 which has been used estimated
from trials conducted in primary care clusters in the UK
[37].
Objective 4
To determine barriers and drivers to the provision of
treatment of tobacco dependence within TB pro-
grammes (qualitative component of Phase III)
Key activities
At this stage we will require an in-depth understanding
of the way intervention would be implemented. We
would like to know which factors would act as barriers
to effective implementation and how health profes-
sionals would overcome these. We would also like to
know the key drivers in the system which would be
instrumental to successful implementation. We would
be interested in understanding to what extent patient
felt supported in their efforts to stop tobacco use
through the health service intervention; which factors
motivated them to quit; and which were their main con-
straints. Since this phase will be post-intervention, it
would be preferable to use semi-structured interviews
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understanding.
Settings and Participants
We will recruit a group of study participants from the
health centres from both urban and rural settings
including:
● Patients who were offered intervention and did not
quit tobacco use
● Patients who were offered intervention and quit
tobacco use
● Doctors and programme managers
● Other paramedical staff.
Sampling
We will purposively select 16 individuals (8 from urban
and 8 from rural settings) equally from all four key
informant groups.
Data collection
We will use an interview topic guide which would be
initially piloted with a patient and a doctor. All commu-
nications will be tape-recorded and transcribed. Key
themes identified from an iterative analysis of focus
group data from phase II will also be used to develop
the interview topic guide.
Data analysis
We will use a sequential focus groups and analysis
process so that the later focus groups can be informed
by and test themes emerging from the earlier focus
group discussions. Data will be categorised and coded
for a thematic analysis. Initial codes, generated from
the focus group in phase II will also be iteratively
updated. Data will be organised to identify key themes.
Dependability of these themes will be checked with
respondents.
Outputs
1. Further refinement of the model of care and
materials to take account of barriers and facilitators
to implementation
2. Useful information to understand the implications
of scaling up the intervention within TB programme
Objective 5
To promote and support long term implementation of
this intervention (Phase IV)
Key activities
Activities listed here will be ongoing throughout the
study period. These include:
● Seek the national TB and Tobacco control pro-
grammes’ endorsements for the intervention
● Work with the national programmes to develop a
plan to scale up the intervention
● Develop a proposal to conduct embedded research
to inform further scaling up.
Discussion
User participation
We will conduct patient focus groups in the first phase
of the project to inform the development of the inter-
ventions, especially patient education tools. We will seek
other opportunities to engage users in the research as
appropriate e.g. we will endeavour to include patient
representatives in the monthly cluster meetings.
Although, we do not envisage reporting the results back
to all research participants, we would convey our find-
ings to the participating communities through local
newspapers, radio, community leaders, patient represen-
tatives in the steering committees and posters in the
participating health centres.
Gender Considerations
We understand that gender is a key determinant of the
attitude towards tobacco use and related behaviour.
Gender also determines the different patterns and types
of tobacco use. Furthermore, women’su p t a k eo fa n d
response to NRT is different from men. The uptake of
both men and women may also differ on the gender of
the professional giving advice. Therefore, we will record
gender of both providers and recipients and conduct
sub-analyses to ascertain variable uptake, response to
the treatment and maintenance of abstinence according
to these gender differences. We will conduct separate
focus groups of both women and men in phase I to cap-
ture gender perspective in attitudes towards tobacco use
and its cessation.
Confidentiality and data protection issues
The privacy of the participating patients will be pro-
tected, and all data will be coded and processed accord-
ing to the rules and policies of University of Leeds.
Ethical considerations
The effectiveness of specific intervention components (e.
g. Bupropion) is established in trials conducted mainly
in developed countries. However, the same is not true
for the strategies that attempt to introduce these into
existing health programmes. The proposed study is eval-
uating the effect of a multifaceted intervention to sup-
port patients who are suspected of TB to give up
nicotine use. The research questions posed here respond
to a priority need for developing countries where the
existing health programmes provide an opportunity to
control the increasing problem of tobacco addiction.
No participant will be deprived of any care that she
would ordinarily receive. There will be no extra burden,
financial or otherwise, on control subjects. Even partici-
pants in the control facilities may benefit from greater
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their first contact is often required for their clinical con-
dition. Upon completion of the trial, all control facilities
will be offered a copy of all the training materials, train-
ing course, desk-guide and education tools. Under-pow-
ered trials are considered unethical[38]; therefore our
sample size calculations are based on conservative esti-
mates and high power.
Formal ethical approval is being granted by the Bio-
medical Ethics Committee of Pakistan Medical Research
Council. An information sheet translated in Urdu will
be given to all eligible patients. Patients will be given
information on all aspects of the research project by
means of verbal and written information at the inclu-
sion. It will be clarified in the informed consent form
that each patient can leave the study at any moment
without having any repercussions on her usual care.
Results and dissemination
Our aim is to ensure that the Pakistan National TB Pro-
gramme and the Pakistan National Tobacco Control
Programme adopts, scales up and sustains the interven-
tion that we expect to arise from this work: that is, that
the research benefits the people of Pakistan and not
merely the researchers. History demonstrates that to
achieve this aim, it is insufficient to follow the conven-
tional approach of disseminating the research results at
the end of the study.
Instead, our approach is to embed research within the
national control programmes, starting even before the
inception of the research and continuing beyond the
end of the research to help the programme develop pol-
icy statements, implementation tools, training materials
and courses. Policy-makers, researchers and other stake-
holders are all involved throughout the process, from
identification of priority problems, through broad devel-
opment of research questions and proposals, regular
feedback on progress of the research, interpretation of
the research findings, and scale-up.
As a result, all stakeholders, including the Directors of
the NTP and NTCP and the research team, have owner-
ship of and responsibility for the research from start to
finish. Thus research questions are asked which are of
direct relevance to the control programme directors;
candidate interventions are feasible in the economic,
socio-cultural and political setting; and issues of scale-
up are addressed at the inception of the research. This
greatly enhances the likelihood that the research find-
ings are incorporated not only into policy, but also into
national practice. We will also make attempts to bring
in other organizations, (e.g. NGOs, lobby groups work-
ing for tobacco control in Pakistan) to help with the dis-
semination of the results and use this research to lobby
for greater tobacco control measures.
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